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Purpose: Multimodality therapy leads to improved outcomes for adenocarcinoma of the distal esophagus and
gastroesophageal junction (GEJ) over surgery alone. At our institution, adjuvant chemoradiation (chemoRT) using
IMRT and SIB is standard of care for resected high-risk disease. In this study, we review our experience with a recent
cohort of patients treated in this manner.
Methods and materials: We identified 18 patients with resected T3 and/or N1 adenocarcinoma of the distal
esophagus and GEJ who received adjuvant chemoRT. A large elective volume (PTV1) and a smaller high-risk volume
(PTV2) were irradiated simultaneously using IMRT and an SIB technique. All patients received concurrent
chemotherapy. Relevant clinical outcomes are reported.
Results: The median dose to 95% of PTV1 was 3747cGy and to 95% of PTV2 was 4876cGy. All RT was given in a
median of 28 daily fractions. Four patients did not complete chemotherapy. At a median follow up of 952 days
from the start of RT, 7 of 18 patients were dead; of these, 3 had developed local recurrence only; 3 had developed
both local and distant recurrence; 1 died of a late toxicity, without recurrence. OS was 88% at 1year, 76% at 2 years
and 58% at 3 years. Freedom from local recurrence was 88% at 1 year, 82% at 2 years and 82% at 3 years. Freedom
from distant recurrence was 72% at 1 year, 67% at 2 years and 56% at 3 years. Toxicity was acceptable.
Conclusions: Adjuvant concurrent chemoRT with IMRT and SIB is feasible for resected high-risk adenocarcinoma of
the distal esophagus and GEJ. Our results describe how modern treatment techniques can be employed as part of
a treatment paradigm that is neither commonly used nor commonly described in the literature.
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The incidence of adenocarcinoma of the distal esophagus,
gastro-esophageal junction (GEJ) and proximal stomach is
increasing [1]. These cancers can grow to an advanced size
before becoming apparent, and they can access an exten-
sive lymphatic network [2], increasing the risk of metastasis
and compromising outcome. For such reasons, the prog-
nosis for this disease remains dismal. The mainstay of
curative-intent treatment is surgery, where outcome corre-
lates with the completeness of surgical resection [3]. Unfor-
tunately, surgery alone is rarely curative if there is nodal
involvement [4], and thus there is a clear need to establish
improved mechanisms for delivering adjuvant therapy.
Individually, the benefits of radiotherapy (RT) and chemo-
therapy beyond surgery are modest [5]. The best outcomes
have been achieved with trimodality therapy, where meta-
analysis has identified significantly improved overall survival
(OS) over surgery alone with the use of induction chemoRT
[6-8]. Based upon such results, neoadjuvant chemoRT has
become the standard of care for resectable carcinoma of the
esophagus andGEJ.
Despite this, adjuvant concurrent chemoRT remains our
institutional standard of care for patients with respectable
carcinoma of the distal esophagus and/or GEJ. Such
patients are taken immediately to surgery, after which
those with pathologically proven T3 or N1 disease are
offered adjuvant chemoRT. Historically, we delivered such
treatment using multiphase 3-dimensional conformal
radiotherapy (3DCRT) techniques [9,10]. We have now
established intensity-modulated radiotherapy (IMRT) with
simultaneous integrated boost (SIB) as our new standard.
We review herein our recent clinical experience with this
novel technique in a cohort of patients.
Methods
Ethics approval
This retrospective review was performed with the ap-
proval of our Institutional Health Sciences Research Ethics
board.
Study population
Between 2007 and 2010, a cohort of 18 patients with
resected adenocarcinoma of the distal esophagus and GEJ
received adjuvant chemoRT. Every patient had pathologic
confirmation of T3 and/or N1 disease. Every patient was
fit enough to tolerate adjuvant aggressive chemoRT. After
treatment, every patient was seen every three months for
the first year, and at least every 6 months thereafter. The
clinical characteristics of our study cohort are presented
in Table 1.
Surgery
Fifteen patients had video-assisted transhiatal esophagect-
omy with cervical anastomosis. One patient had transhiatalesophagectomy with right video-assisted mobilization of
the esophagus. One patient required trans-thoracic esopha-
gectomy with thoracotomy (three-hole esophagectomy).
One patient required open transhiatal esophagectomy with
laparotomy. All technically accessible lymph nodes were
removed from the lower thoracic and upper abdominal
nodal basins. Marking clips were placed to guide adjuvant
radiotherapy treatment planning.
Chemotherapy
Prior to the start of RT, patients received two cycles of
epirubicin-cisplatin-5-fluorouracil (ECF) alone (epirubi-
cin: 50 mg/m2; cisplatin: 60 mg/m2; 5FU infusion: 200
mg/m2•d). This was followed by a further two cycles of
CF given concurrently with RT (cisplatin: 60 mg/m2;
5FU infusion: 200 mg/m2•d). Each cycle was 3 weeks in
duration, with the understanding that any cycle(s) could
be given at reduced dose (or withheld altogether) at the
discretion of the treating Medical Oncologist.
Radiotherapy treatment planning
General
All patients went for CT simulation during cycle 2 of
chemotherapy. Prior to 2008, free-breathing CT simula-
tion scans were standard. From 2008 onward, we used
4-dimensional CT (4DCT) to incorporate respiratory
motion. Motion management was established using
the Real-Time Position Management™ (RPM™) system
(Varian Incorporated, Palo Alto, CA). All patients were
immobilized with arms up, in a vacuum fixation device.
Intravenous and oral contrast agents were not used.
Delineation of ICRU target volumes
We defined two clinical target volumes (CTV). Lower-
dose volume CTV1 covered nodal basins at risk of harbo-
ring metastatic disease: the celiac axis, porta hepatis and
splenic hilar nodes in the abdomen, and levels 1 through 8
in the mediastinum. In all cases, the superior border of
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volume CTV2 covered the pre-surgical location of the
primary disease, any bulky adenopathy and sites of close
or positive margins. In general, CTV2 included the lower
mediastinum and upper abdomen. For a single patient,
CTV2 also included the anastomosis because of a close
longitudinal surgical margin.
Prior to 2008, we applied margins of 1 cm superiorly-
inferiorly and 5 mm radially to CTV 1 and CTV2 to
account for tumor motion. From 2008 onwards, once
4DCT became standard, we delineated CTV1 and CTV2
on both the full-expiration and full-inspiration images to
account for respiratory motion. We then added an iso-
tropic margin of 3 mm to account for residual motion,
defining internal target volumes (ITV) ITV1 and ITV2.
Finally, we added a 5 mm isotropic margin around ITV1
and ITV2 for setup, defining planning target volumes
(PTV) PTV1 and PTV2.
Figure 1 depicts a typical example of PTV1 and PTV2.
Prescription dose
Historically, we treated these patients in two phases using
3DCRT: in phase 1, a large elective volume, including the
anastomosis, was treated to 3600 cGy in 20 daily fractions.
Our decision to include the anastomosis was rooted in
RTOG 8501, where essentially the entire mediastinum
was treated to 3600 cGy in 20 fractions [11]. In phase 2,
the high-risk boost volume was treated to 1440 cGy in 8
daily fractions (5040 cGy in 28 fractions total). RadiationFigure 1 Beam’s-eye View: Target Volumes for IMRT in a 65
year-old male with resected T3N1 adenocarcinoma of the distal
esophagus and GEJ. PTV1, encompasses abdominal nodes,
mediastinal nodes and anastomosis. PTV2, covers the pre-operative
site of disease and any close or positive surgical margins.portals for the phase 2 boost were defined according to
pre-operative imaging and pathology [9].
PTV1 and PTV2 represent the modern cognates of our
previous technique [10]. PTV1 and PTV2 were treated
using a simultaneous integrated boost (SIB) technique. All
treatment was delivered using IMRT. PTV1 was pre-
scribed a nominal dose of 3900 cGy in 28 daily fractions,
representing a biologically equivalent dose to our histo-
rical standard of 3600 cGy in 20 fractions. PTV2 was, for
most patients, prescribed a nominal dose of 5040 cGy in
28 daily fractions; two patients were prescribed 5400 cGy
in 30 daily fractions, with the higher dose selected because
of close surgical margins at the original tumor location.
Organs at risk
Dose to normal tissues was limited according to published
standards [12,13]. For the lung, we defined an evaluable
lung volume as the total lung less any overlap with CTV1
(TL-CTV1). This volume was typically limited to 20 Gy to
≤30%, and a mean dose of 18 Gy or less.
Dosimetric comparison
Because our new technique represents a revision of our
previous technique, a dosimetric comparison of our his-
torical cohort and our current cohort would be instruc-
tive. Unfortunately, our historical cohort was planned
using either an outdated treatment planning system (now
decommissioned), or using plain-film radiography. Either
way, a detailed dosimetric analysis of our original cohort
is no longer possible. However, it is possible to re-plan our
modern cohort using our previous technique [9]. We per-
formed this comparison for all 18 cases. The 3DCRT plan
was prescribed to 3600 cGy in 20 fractions to PTV1, fol-
lowed by a sequential boost of 1440 cGy in 8 fractions to
PTV2; the IMRT-SIB plan was planned to 3900 cGy to
PTV1 and 5040 cGy to PTV2, given concurrently in 28
fractions via an SIB technique. For the purpose of this
comparison, the prescription isodose for the 3DCRT plan
was adjusted until the dose covering 95% of PTV2 (the
D95) was the same as that for the IMRT-SIB plan. Corre-
sponding dosimetric data were generated, and a statistical
comparison was performed via a 2-sided, paired t-test.
Results
Treatment delivered
RT was initiated at a median of 120 days after surgery.
The majority of patients (14 of 18) completed all pre-
scribed RT. For 3 of the remaining 4 patients, 21, 24
and, 26 of the intended 28 fractions were delivered; for
the fourth patient, 29 of the intended 30 fractions were
delivered. The median delivered number of fractions was
28. Both PTV1 and PTV2 were adequately covered. As-
treated dosimetric results are presented in Table 2.
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Analysis was performed at a median follow up of 952 days
from the start of RT (or 1065 days from the date of sur-
gery). Recurrences were defined as the earliest instance of:
radiographic evidence; biopsy evidence; or abnormality on
direct clinical examination. Kaplan-Meier survival curves
are presented in Figure 2. Estimated overall survival (OS)
was 88% at 1 year, 76% at 2 years and 58% at 3 years.
Median OS was 3.0 years. Freedom from local recurrence
(LR) was 88% at 1 year, 82% at 2 years and 82% at 3 years.
Freedom from distant recurrence (DR) was slightly worse,
72% at 1 year, 67% at 2 years and 56% at 3 years. Median
LR-free survival and DR-free survival were not reached.
At the time of analysis, 7 of 18 patients were dead: 3
deaths occurred in patients who experienced both LR and
DR; 3 deaths were in patients who experienced only DR; a
single patient died of a late toxicity (discussed below)
without experiencing either LR or DR. Three of 7 deaths
were in patients who had not completed the prescribed




Toxicity was graded retrospectively using the Common
Toxicity Criteria for Adverse Events (CTCAE) version
4.03 [14].
Acute toxicity
For the purposes of this review, “acute” was defined as ≤
180 days from the start of RT.
Nine of 18 patients experienced acute esophageal toxicity.
There were five cases of acute esophagitis (grade 1: n = 4;
grade 2: n = 1), occurring at a median of 26 days after star-
ting RT. There were 4 cases of acute stricture requiring
dilatation (grade 3), occurring at a median of 37 days after
starting RT. For 3 of these, dilatation occurred 36, 37 and
41 days after starting RT; for the fourth, dilatation occurred
86 days prior to the start of RT (or 121 days after surgery).Table 2 Resultant dosimetry of clinically treated cohort
Metric Mean Stdev Median
intended fractions 28 0.6 28
delivered fractions 27 2.0 28
volume PTV1 (cm3) 1806 506.8 1663
volume PTV2 (cm3) 306 221.8 281
PTV2 / PTV1 0.17 0.10 0.14
PTV1: mean dose (cGy) 4167 310.7 4207
PTV1: D95* (cGy) 3604 320.8 3747
PTV2: mean dose (cGy) 4954 364.1 5074
PTV2: D95* (cGy) 4780 332.6 4876
*D95: dose delivered to ≥ 95% of reference volume PTV1 or PTV2.
Figure 2 Kaplan-Meier survival curves for (a) overall
survival; (b) local recurrence; and (c) distant recurrence
(full dataset, n = 18). Analysis was performed at a median
follow up of 952 days after start of RT (or 1065 days from the
date of surgery). Overall survival was 88% at 1 year, 76% at 2
years and 58% at 3 years. Freedom from local recurrence was
88% at 1 year, 82% at 2 years and 82% at 3 years. Freedom
from distant recurrence was 72% at 1 year, 67% at 2 years and
56% at 3 years.
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tracheo-esophageal fistula (TEF) 54 days after starting RT,
requiring early discontinuation of RT (26 of 28 fractions
completed) and urgent surgical repair. The affected patient
was free of recurrence at the time of this analysis (238 days
after start of RT).
Six of 18 patients experienced acute pulmonary toxicity.
There were 2 cases of acute aspiration pneumonitis, occur-
ring 36 days (grade 2) and 97 days (grade 1) after the start
of RT (or 167 and 218 days after surgery). Four patients
experienced acute grade 1 non-aspiration pneumonitis,
without evidence of aspiration on imaging, occurring at a
median of 35 days after starting RT.
There were 3 cases of acute grade 1 nausea, 2 cases of
acute grade 2 nausea, and 2 cases of acute grade 3 nausea,
occurring at a median of 0 days prior to the start of RT. In
other words, 4 patients already had established nausea
prior to initiation of RT.
Fourteen of 18 patients completed all 4 cycles of chemo-
therapy. Of the 4 patients who did not, 3 completed 3
cycles, while 1 patient (age 86) completed 1 only cycle
before stopping voluntarily (this same patient also volun-
tarily discontinued RT after only 21 of 28 prescribed
fractions). Thirteen of 18 patients experienced acute neu-
tropenia, occurring at a median of 20 days prior to the
start of RT (grade 1: n = 2; grade 2: n = 7; grade 3: n = 3;
grade 4: n = 1). All 18 patients experienced acute lympho-
penia (grade 1: n = 0; grade 2: n = 1; grade 3: n = 6; grade
4: n = 11), occurring at a median of 32 days prior to the
start of RT. Fifteen of 18 patients experienced acute
thrombocytopenia (grade 1: n = 8; grade 2: n = 6; grade 3:
n = 1; grade 4: n = 0), occurring at a median of 13 days
after the start of RT. In total, 14 patients required either a
1-week delay in at least 1 chemotherapy cycle or a dose-
reduction of at least 1 chemotherapy agent.
Late toxicity
Three patients experienced clinically significant late
toxicity. One patient developed grade 5 (fatal) aspiration
pneumonitis 357 days after the start of RT. This
occurred several months after the patient developed
both LR and widespread DR. The patient was debilitated
and frail and died only 1 day after aspirating. A second
patient experienced esophageal stricture 528 days after
starting RT. This patient did not experience acute stric-
ture and responded very well to dilatation. At the most
recent follow up assessment, the patient was alive and
free of recurrence (966 days after the start of RT). A
third patient experienced TEF and grade 5 aspiration
pneumonitis 761 days after the start of RT. This patient
required multiple dilatations, before, during and after che-
moRT and eventually required stricturoplasty, 18 months
after the start of RT. Approximately 7 months after stric-
turoplasty, this patient experienced an acute breakdown ofboth the transposed esophagus and trachea, leading
directly to aspiration and death. At the time of death, the
patient‘s disease was under control, with no clinical evi-
dence of LR or DR.
We identified 11 cases of late lymphopenia, with mildly
decreased lymphocyte count persisting at a median of 319
days after start of RT. For 3 of these patients, lymphocyte
counts eventually returned to normal levels. For the
remaining 8 patients, lymphocyte counts remained per-
sistently yet mildly decreased on all subsequent follow-
up. We did not identify any late neutropenia or late
thrombocytopenia. We did not identify any late nausea.
Dosimetric comparison
The results of our dosimetric comparison of IMRT-SIB
and 3DCRT for the full cohort are presented in Table 3.
For normal lung (i.e. total lung less CTV1), the use of
IMRT-SIB enabled a significant reduction in V20 and
MLD; however IMRT-SIB was associated with a signifi-
cant increase in V10 compared to 3DCRT. IMRT-SIB
also enabled significantly reduced dose to the liver, heart,
and cord, along with a non-significant reduction in dose
to the kidneys.
Discussion
In this retrospective review of patients with resected
high-risk adenocarcinoma of the distal esophagus and
GEJ, we describe a novel technique for the delivery of
adjuvant chemoRT.
In North America, neoadjuvant chemoRT is the esta-
blished standard of care for resectable carcinoma of the
distal esophagus and GEJ [6-8]. By comparison, the rou-
tine use of adjuvant chemoRT is far less common. The
published literature regarding adjuvant chemoRT for
resected carcinoma of the distal esophagus is character-
ized mostly by single-institution studies and retrospect-
ive reviews, representing a variety of approaches. Our
original retrospective study suggested an OS benefit to
adjuvant chemoRT over surgery alone, with median
overall survival (OS) being extended to 47.5 months
with adjuvant chemoRT versus 14.1 months without
(p = 0.001) [9]. Irradiation of the anastomosis was asso-
ciated with a significant improvement in local and
regional relapse [10] and reduced recurrence at the
anastomotic site [15], implying the importance of local
control as a determinant of outcome [16]. Similar bene-
fits of adjuvant chemoRT have been recognized by other
authors [17-19].
A comprehensive review of the literature regarding adju-
vant chemoRT for resectable carcinoma of the esophagus
is provided as an online supplement (Additional file 1).
Adjuvant chemoRT with IMRT-SIB has become our
new institutional standard of care for patients with resect-
able carcinoma of the distal esophagus and GEJ. Our
Table 3 Dosimetric comparison within the same cohort: IMRT-SIB technique versus classic 3DCRT technique
Metric IMRT-SIB 3DCRT p (2-sided t-test)
V20 (TL-CTV1) (−) 0.30 0.40 < 0.005
V10 (TL-CTV1) (−) 0.68 0.54 < 0.005
mean dose (TL-CTV1) (cGy) 1616.9 1760.4 0.070
liver mean dose (cGy) 1748.3 1919.2 0.10
heart mean dose (cGy) 2981.2 3582.9 < 0.005
cord maximum (absolute) (cGy) 4175.0 4587.3 < 0.005
cord maximum (2 cm3 volume) (cGy) 3935.9 4422.5 < 0.005
right kidney mean dose (cGy) 474.2 641.8 0.29
left kidney mean dose (cGy) 645.4 966.0 0.26
mean value of (D95*/prescription dose) for PTV1 (−) 0.97 0.98 0.70
mean value of (D95*/prescription dose) for PTV2 (−) 0.97 0.98 0.48
*D95: dose delivered to ≥ 95% of reference volume PTV1 or PTV2.
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historical technique [9]. We developed our IMRT-SIB
technique for several reasons. In general, IMRT-SIB
provides efficiency and convenience relative to 3DCRT.
Instead of 2 separate phases of treatment, we need to plan
only a single course of treatment, while quality assurance
is more efficient than with 2 separate 3DCRT plans. As
well, because IMRT had already become established for
the treatment of several other disease sites at our institu-
tion, we were familiar with its application, delivery and
potential clinical and dosimetric benefits, and we were
hopeful that IMRT would extend those same benefits to
our patients with resected high-risk carcinoma of the
esophagus.
Nonetheless, a new technique is not necessarily better
simply because it is more technologically advanced. In
order to be a true improvement, it must also confer a
demonstrable benefit in terms of dosimetry and clinical
outcomes, and of course it must be able to do so safely.
Our results suggest a considerable dosimetric benefit of
IMRT-SIB over 3DCRT. DVH curves (Figure 3) and corre-
sponding dose-distributions (Figure 4) are presented for a
single illustrative case. In this example, IMRT-SIB gives
improved dosimetry over the entire range of dose for
nearly every region of interest except the lung (here repre-
sented by TL less CTV1) and the heart. For these 2 struc-
tures, 3DCRT produces more favorable dosimetry in the
low-dose range than does IMRT-SIB. The benefit of
3DCRT in this range is due to the fact that 3DCRT
requires fewer beams, and that such beams typically have
distinct field-edges, reducing low-dose scatter compared
to IMRT. IMRT-SIB is better in the higher-dose range due
to the greater conformality that is possible with IMRT. In
general, the larger doses to the mediastinal structures that
are delivered using 3DCRT would tend to render 3DCRT
less desirable than IMRT-SIB in actual clinical practice.We compared the observed clinical outcomes of our
IMRT-SIB cohort to a previous cohort that we treated
using our 3DCRT technique [15]. The relevant results of
this comparison are presented in Table 4. Although our
outcomes with IMRT-SIB appear to be at least as good
as those achieved using 3DCRT, such an interpretation
is inherently difficult. We cannot be sure that any
observed improvements are due solely to our new tech-
nique because comparisons across studies are always dif-
ficult, due to such factors as stage migration, improved
diagnostic techniques, improved surgical techniques and
inter-observer variations in clinical grading and assess-
ment, in addition to the small sample sizes.
One of the potential detriments with our IMRT-SIB
technique is the fact that the target volume encompasses
the anastomosis, thereby potentially treating a substantial
amount of normal lung. It is intriguing that our modern
cohort seemed to experience more acute pulmonary tox-
icity than our historical cohort (Table 4). If the results of
our dosimetric comparison (Table 3) are in fact correct,
then our 3DCRT technique would have treated the normal
lung to a much higher V20 than with IMRT-SIB, corres-
pondingly raising the risk of radiation-induced lung injury.
It is possible that the incidence of radiation-induced lung
injury was simply under-reported in our original cohort.
On the other hand, the significantly increased V10 that we
identified for IMRT-SIB over 3DCRT might actually pre-
cipitate acute radiation-induced lung injury at a faster rate
than would 3DCRT. Interestingly, a recently published
series from China did not identify a single case of acute
radiation-induced pulmonary toxicity in a cohort of 78
patients receiving adjuvant chemoRT [20]. In that series,
30 of 78 patients were treated to 50 Gy to the lower medi-
astinum and upper abdomen, while an additional 48
patients were treated to this same dose using an extended
field, encompassing the sixth cervical vertebra to the first
Figure 3 Example DVH Comparison: IMRT-SIB versus 3DCRTfor: (a) PTV1; (b) PTV2; (c) TL-CTV1; (d) cord; (e) liver; (f) heart (same
patient as Figure 1). IMRT-SIB (thick lines) and 3DCRT (thin lines) are compared directly for a single illustrative case. IMRT-SIB is more conformal
about PTV1 than 3DCRT, with a lower mean dose and a more pronounced dose-gradient from PTV1 to PTV2. There is similar coverage of PTV2.
For TL-CTV1 and liver, 3DCRT has better dosimetry in the low-dose region but is worse in the higher-dose region. IMRT-SIB delivers consistently
better dosimetry to the heart and the cord over the entire range of dose.
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roughly described, it appears that they delivered all treat-
ment using 3DCRTas opposed to IMRT.
Much of our observed toxicity was either expected
(hematologic toxicity in response to chemotherapy) or was
clinically insignificant (low-grade pulmonary toxicity). Thethree most significant observed toxicities were an acute
TEF, a late grade 5 aspiration pneumonitis, and a late TEF
with simultaneous grade 5 aspiration pneumonitis. The
acute TEF occurred within low-dose PTV1, in a patient
who required almost-weekly endoscopic dilatation, imply-
ing the role of mechanical injury. The late grade 5
Figure 4 Example Dosimetric Comparison: IMRT-SIB versus 3DCRT (same patient as Figure 1). IMRT-SIB (top) exposes mediastinal
structures to generally lower doses than 3DCRT (bottom), conferring considerable potential clinical benefit over 3DCRT.
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start of RT, in a debilitated patient with widely metastatic
recurrent disease. Finally, the late grade 5 aspiration pneu-
monitis occurred more than 2 years after days after the
start of RT, while the TEF was again within low-dose













pulmonary toxicity (≤90 days)
esophageal toxicity (≤90 days)
pulmonary toxicity (>90 days)
esophageal toxicity (>90 days)The occurrence of two grade 5 toxicity events is clearly a
cause for concern. However, it is not possible to ascertain
the significance of this observation from our small, retro-
spective cohort. We note that grade 5 toxicity was not
observed in our previously reported series using 3DCRT
[15]. Given the similarity of surgical techniques betweencohort and published 3DCRT cohort [15]
IMRT-SIB 3DCRT [15]
(n = 18) (n = 15)
952 days 570 days (19 months)
not reached 690 days (23 months)
88% 80%
82% 44%
3 years (36 months) 1.8 years (21 months)
88% 65%
76% 38%
3 (17%) 0 (0%)
7 (39%) 6 (40%)
4 (22%) 2 (15%)
9 (50%) 1 (7%)
5 (28%) 3 (20%)
1 (6%) 2 (13%)
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given the radiobiological similarity between our current
and previous dose-fractionation regimes, at the very least
we expect IMRT-SIB to be comparable in terms of acute
and late toxicity to our previous technique, with compar-
able survival.
Additional study is therefore required to characterize
the efficacy and potential toxicity of our adjuvant IMRT-
SIB technique more fully. To this end, we are assessing
IMRT-SIB as part of a randomized-controlled clinical trial
comparing adjuvant chemoRT and neoadjuvant chemoRT
directly, using quality of life as our primary endpoint [21].
Conclusion
We presented the results of a modern cohort of patients
with resected, high-risk adenocarcinoma of the distal
esophagus and GEJ, treated with adjuvant chemoRT using
IMRT-SIB. Our approach is novel and feasible. Although
our approach is associated with acceptable local control
and reasonable survival, long-term safety and efficacy still
need to be defined. To our knowledge, our study is the
first to report the use of IMRT techniques and SIB techni-
ques in this clinical setting. We hope that our experience,
as reported here, will be useful to other clinicians when
treating this challenging patient population.
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